Quo Labs
Building emotionally intelligent eldercare robots for every care and family home, starting with Sam.
Website: https://www.quolabs.ai/
Cover Block
Public sources
| Name | Quo Labs |
| Tagline | Building emotionally intelligent eldercare robots for every care and family home, starting with Sam. [quolabs.ai, retrieved 2026] |
| Headquarters | San Francisco, United States |
| Founded | 2025 [Founders, Inc.] |
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
Links
Public sources
- Website: https://www.quolabs.ai/
- LinkedIn: https://www.linkedin.com/company/quo-labs
Executive Summary
Public sources
Quo Labs is building emotionally intelligent eldercare robots, a venture that merits attention for its attempt to address one of the most persistent and growing structural challenges in developed economies: the unsustainable cost and labor shortage of senior care. The company, founded in 2025 by Audrey Lo, Jenny Wen, and Kai Leviyang, is developing its first product, a home robot named Sam, which aims to provide seniors with help, companionship, and peace of mind directly in family homes [quolabs.ai, retrieved 2026]. The founding team is described as ex-Columbia students who have published AI research cited by the Mayo Clinic and scaled products to millions in revenue, a background that suggests technical credibility and operational experience [quolabs.ai, retrieved 2026]. The company has participated in the a16z Speedrun program, which provides some early-stage validation, but no formal funding rounds or named investors have been publicly disclosed [a16z Speedrun]. Over the next 12-18 months, the key signals to watch will be the transition from program participation to a priced equity round, the publication of verifiable pilot data to support claims of deployment in over 50 families, and the articulation of a clear hardware-plus-software business model that can deliver on the promise of affordability.
Lightly corroborated -- Core product and team claims are sourced from the company website and program listings; market sizing data is also from the company. Key operational claims, such as customer deployments, are not yet corroborated by independent primary sources.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
How the Company Got Here
Public sources
Quo Labs is a San Francisco-based robotics company founded in 2025 by Audrey Lo, Jenny Wen, and Kai Leviyang [quolabs.ai, retrieved 2026]. The founders are described as ex-Columbia students who have published AI research cited by the Mayo Clinic and scaled products to millions in revenue, with their motivation stemming from firsthand observation of gaps in eldercare [quolabs.ai, retrieved 2026] [Aparobot].
The company's primary public milestone is its participation in the a16z Speedrun program, an accelerator for early-stage startups [a16z Speedrun]. A third-party article claims the company's first product, a home robot named Sam, has been deployed in over 50 families, but this claim is not corroborated by primary company sources [Aparobot]. No other major funding rounds, customer announcements, or product launches are documented in public sources.
Lightly corroborated -- Core founding details confirmed by company website and accelerator listing; deployment claims are from a single unverified source.
Product and Technology
Sources and analysis Quo Labs is building a hardware and software system, not an application. The company's first product, Sam, is a home robot designed to provide seniors with help, companionship, and peace of mind [quolabs.ai, retrieved 2026]. The core technical claim is the development of "emotionally intelligent" eldercare robots, which suggests a focus on AI models capable of interpreting and responding to human emotional cues, a significant technical hurdle beyond basic task automation.
The product's intended environment is the family home, positioning it as a consumer-facing device for caregivers and seniors rather than an institutional tool [quolabs.ai, retrieved 2026]. While specific hardware capabilities, sensor suites, and software interfaces are not detailed in public materials, the wedge appears to be everyday interaction and companionship. An unverified third-party article claims Sam has been deployed in over 50 families, but this deployment scale and the nature of the pilot are not corroborated by primary company sources [Aparobot].
Lightly corroborated -- Product description confirmed by company website; deployment claims from a single unverified source.
Where the Demand Sits
Public sources The demographic shift toward an older global population is creating a structural demand for eldercare solutions that existing systems are not equipped to meet.
Quo Labs frames its market opportunity around a set of cited macro pressures. According to the company's website, 80% of older Americans cannot afford long-term care [quolabs.ai, retrieved 2026]. This affordability gap is compounded by a projected shortage of 4 million healthcare professionals in the United States [quolabs.ai, retrieved 2026]. The company also cites the average American family paying $7,600 annually for caretaking as a baseline cost of the status quo [quolabs.ai, retrieved 2026]. These figures point to a market defined by high unmet need and significant economic strain on families.
The primary demand driver is a straightforward demographic tailwind. The company cites a projection that by 2030, 1 in 6 people globally will be aged 60 years or over [quolabs.ai, retrieved 2026]. This aging population creates a growing base of potential users for assistive technologies. The market is not limited to traditional medical care but extends to the broader category of daily living assistance and companionship, areas where labor shortages are acute and family resources are stretched.
Key adjacent markets include the broader home health technology and consumer robotics sectors. While Quo Labs targets an eldercare infrastructure layer, its product's functionality could overlap with substitute markets like remote patient monitoring platforms, telehealth services, and non-specialized consumer smart home devices. Regulatory forces, particularly those governing medical devices, data privacy (HIPAA in the U.S.), and liability for in-home care, will be a critical factor shaping the commercial landscape and adoption timeline for any physical care robot.
| Metric | Value |
|---|---|
| Projected Global Population 60+ by 2030 | 1.67 billion (estimated) |
| Annual U.S. Family Caretaking Cost | 7.6 $K |
| U.S. Healthcare Professional Shortage | 4 million |
The cited figures sketch a market characterized by immense scale, high cost, and systemic labor constraints. The 1.67 billion global projection for the 60+ population by 2030, derived from the company's 1-in-6 statistic applied to a UN-projected global population, represents the ultimate addressable audience, while the $7.6k annual cost and 4 million professional shortfall quantify the immediate pressures creating the opening for a new solution.
Lightly corroborated -- Market sizing claims are sourced solely from the company's website; demographic projections are consistent with public UN data but lack independent third-party citation for the specific figures presented.
Competitive Landscape
Sources and analysis Quo Labs enters a market defined by a stark gap between the scale of the demographic need and the availability of effective, affordable solutions.
No named competitors were identified in the provided sources, which is itself a notable data point for a pre-seed company. The competitive map for eldercare robotics and assistance is therefore drawn from adjacent segments and potential entrants rather than direct, head-to-head rivals. The landscape can be segmented into three broad categories.
- Incumbent healthcare providers. Large home health agencies and senior living facilities represent the primary current solution, competing on the basis of human labor and established reimbursement pathways. Their advantage is regulatory familiarity and payer relationships, but their core constraint is the same labor shortage Quo Labs cites.
- Challenger tech platforms. This includes telehealth services, remote monitoring systems, and medication management apps. These are software-only solutions that address discrete aspects of care, such as virtual consultations or fall detection. They compete on cost and scalability but lack the physical presence and interactive companionship a robot like Sam proposes.
- Adjacent robotics entrants. This is the most relevant adjacent category, encompassing consumer robotics companies (e.g., Amazon with Astro) and specialized assistive device makers. Their advantage is often manufacturing scale and consumer brand recognition, but their focus has not been exclusively on the nuanced, emotionally intelligent eldercare use case Quo Labs describes.
Quo Labs's stated edge today rests on two pillars: its specific product wedge and its founding team's claimed expertise. The wedge is emotional intelligence and companionship framed as infrastructure, a positioning that attempts to transcend a purely utilitarian tool. The founders' background in AI research cited by a clinical institution like the Mayo Clinic [quolabs.ai, retrieved 2026] is presented as a talent and technical differentiator, suggesting a focus on clinically relevant interaction models rather than general-purpose robotics. This edge is perishable, however, as it relies entirely on unproven execution in hardware development, clinical validation, and user adoption. Without protected IP or exclusive data partnerships disclosed, the concept is replicable by better-capitalized players.
The company's most significant exposure is to well-funded robotics or consumer electronics companies deciding to prioritize the senior care segment. A competitor with existing hardware platforms, supply chain mastery, and direct-to-consumer sales channels could out-execute on distribution and cost before Quo Labs achieves scale. Furthermore, Quo Labs is exposed in the regulatory and reimbursement domain, a complex area where incumbents have decades of experience and new medical device entrants face long approval cycles. The lack of disclosed pilots or partnerships with established care providers [PUBLIC] leaves this go-to-market risk unmitigated in the public record.
The most plausible 18-month scenario involves validation through controlled, small-scale deployments. The winner in this scenario is a company that successfully demonstrates not just user satisfaction but measurable outcomes,reduced caregiver burden, improved medication adherence,that attract institutional buyers or payer contracts. The loser is a company that remains in the prototype or limited family trial phase, unable to transition from a novel concept to a commercially viable product with a clear path to unit economics. For Quo Labs, the specific claim of deployment in over 50 families, while uncorroborated by primary sources [Aparobot], points to the kind of early traction that would be necessary to avoid the latter outcome.
Lightly corroborated -- Competitive analysis is inferred from market structure; no direct competitors were named in available sources.
Opportunity
Public sources The prize for a company that can reliably automate even a fraction of the daily care burden for aging populations is measured in tens of billions of dollars, a figure anchored in the sheer scale of unmet demand and current spending.
The headline opportunity for Quo Labs is to become the foundational hardware and software platform for in-home eldercare, a category-defining layer that sits between the senior, the family, and the professional care system. This outcome is reachable not because of speculative technology but because the core problem is structural: the company cites a shortage of 4 million healthcare professionals in the United States and the fact that 80% of older Americans cannot afford traditional long-term care [quolabs.ai, retrieved 2026]. A platform that demonstrably reduces caregiver burden and delays institutionalization would tap into a multi-sided market of families, insurers, and care providers, moving from a single-purpose robot to an integrated care operating system.
Growth would likely follow one of several concrete paths, each with a distinct catalyst.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| The Family Subscription Model | Sam becomes a standard household appliance for families with aging parents, sold through direct-to-consumer channels and bundled with a monthly care monitoring service. | A successful, publicly documented pilot with a senior living community or a large regional health system validates the reduction in caregiver stress and hospital readmissions. | The average American family already pays $7,600 annually for caretaking, creating a clear price anchor for a subscription service [quolabs.ai, retrieved 2026]. The founders' claimed background in scaling products to millions in revenue suggests a focus on unit economics and growth [quolabs.ai, retrieved 2026]. |
| The Health Plan Partnership | Quo Labs transitions from a DTC company to a B2B2C infrastructure provider, with Sam devices distributed and subsidized by Medicare Advantage plans or large insurers as a cost-containment tool. | A partnership announcement with a named insurance carrier or accountable care organization (ACO) to run a value-based care pilot. | The company positions itself as part of the "eldercare infrastructure layer" [Aparobot], a framing that aligns with the risk-bearing incentives of payers seeking to manage the high cost of an aging member base. |
Compounding for Quo Labs would be driven by a data flywheel specific to in-home elder care. Each interaction with a senior user generates behavioral and health data that, with appropriate consent and privacy safeguards, could refine the robot's emotional intelligence and predictive capabilities. This creates a product improvement loop: better companionship and more accurate alerts increase user retention and satisfaction, which in turn drives more usage and data. Early, though uncorroborated, claims of deployment in over 50 families [Aparobot] suggest an initial effort to gather this real-world interaction data, which is a prerequisite for the flywheel to begin spinning.
The size of the win, should the company capture a meaningful segment of the home-based care market, can be contextualized by looking at adjacent categories. While no direct public comparable exists for an emotionally intelligent eldercare robot, the broader home health and personal care market is vast. For a scenario where Quo Labs establishes a premium subscription service adopted by even a single-digit percentage of the tens of millions of U.S. households managing elder care, annual recurring revenue could reach hundreds of millions of dollars. As a scenario, not a forecast, this scale would support a valuation comparable to other venture-backed healthtech platforms that have successfully inserted themselves into the care delivery workflow.
Lightly corroborated -- The market problem and demographic tailwinds are well-cited from the company's own materials. The growth scenarios are plausible extrapolations from the company's stated positioning, but specific catalysts and the early deployment claim rely on a single third-party source with an unknown date.
Sources
Public sources
[quolabs.ai, retrieved 2026] Quo Labs | https://www.quolabs.ai/
[Founders, Inc.] Quo Labs , AI caretakers for the elderly. | Unknown
[a16z Speedrun] Quo Labs - a16z speedrun | Unknown
[Aparobot] Care Meets Compassion: The Story of Quo Labs and the Future of Elderly Healthcare | Unknown
Articles about Quo Labs
- Quo Labs Builds a Robot for the Loneliest Room in the House — The a16z Speedrun-backed startup is developing Sam, an emotionally intelligent companion for seniors, targeting a demographic shift and a care shortage.